Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

This study found that both 2% and 3% minoxidil resulted in a significant increase in hair counts for participants with androgenetic alopecia over 12 months.

In this study, minoxidil treatment was associated with an increase in nonvellus scalp hairs, but this effect was not sustained once the treatment was stopped.

Minoxidil effectively regrows hair in male pattern baldness.

This study found that minoxidil 2% increased nonvellus hair counts in women with female androgenetic alopecia without causing serious side effects, compared to a placebo.

This study found that nanoemulsions incorporating skin penetration enhancers significantly increased the permeation of minoxidil through human skin compared to aqueous control solutions.

Minoxidil can help grow hair and make hair follicles bigger, but it can also cause side effects.

Using minoxidil on balding men's scalps can increase hair growth, according to a 12-month study.

This study found that topical application of 2% minoxidil solution was not effective in improving erectile dysfunction in the majority of participants.

This document studied minoxidil in healthy volunteers. Minoxidil is quickly absorbed and eliminated from the body.

Method measures minoxidil in tablets accurately and easily.

This letter to the editor compares the efficacy and safety of bimatoprost 0.03% with minoxidil 3% for eyebrow enhancement but does not report any study results.

This study suggests that minoxidil 2% lotion is a safe and effective treatment for enhancing eyebrows, showing better results than placebo after 16 weeks.

The authors describe a case of syncope in a young man after using high strength topical minoxidil, which resolved when he stopped the treatment, highlighting a rare documented reaction.

This study found that an optimized microemulsion for minoxidil with high solubility, permeation flux, and skin deposition can be achieved with specific low and high levels of certain surfactants and co-solvents.

This study highlights the complex clinical issues associated with using low dose oral minoxidil for alopecia, emphasizing the need for careful cardiology-dermatology collaboration due to rare but serious cardiovascular risks, especially in patients with existing cardiorenal or cardiovascular concerns.

A toddler who accidentally swallowed hair growth medicine experienced serious heart-related side effects but recovered after hospital treatment.

This study found that a novel 15% topical minoxidil solution achieved a clinically significant hair regrowth response in 60% of women with female pattern hair loss who did not respond to 5% minoxidil, without increasing adverse events.

In this study, intradermal therapy with Minoxidil, growth factors, and vitamins showed a slight advantage in increasing hair volume over a combination with Finasteride for androgenic alopecia.

This study is the first to examine adherence to topical minoxidil among alopecia patients, identifying factors such as age, sex, and educational level associated with adherence levels.

This study found that the nanostructured lipid carrier gel containing minoxidil showed good consistency and a prolonged drug release in vitro, suggesting potential for treating alopecia.

This study found that chitosan microparticles containing minoxidil sulphate sustained its release and may hold potential for targeted topical treatment of alopecia.

This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.

This study found that minoxidil nanoparticles increased drug delivery to hair follicles and improved hair growth more effectively in mice than conventional minoxidil formulations.

This study identified a weak interaction between minoxidil and ß-cyclodextrin in solution, forming an inclusion complex with a 1:1 molar ratio.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

This study observed that local injection of minoxidil effectively prevented Ara-C-induced alopecia in newborn rats, while topical application was ineffective.

This review discusses the use of topical and oral minoxidil for pediatric hair disorders, pointing out the lack of guidelines and the potential risks associated with systemic absorption, but reports no clinical results.

This study observed that adding low-level light therapy with the GentleWaves® device to Minoxidil significantly boosted hair regrowth in men with androgenetic alopecia by reducing scalp inflammation.

This study reported that polymeric nanofibers containing minoxidil sulphate showed effective encapsulation and stability, with minimal concentration loss over six months, making them potentially ideal for delivering this unstable drug in a more visually appealing and easier-to-apply form.